Other formats:
BibTeX
LaTeX
RIS
@article{1781892,
author = {Lobello, Cosimo and Tichý, Boris and Bystrý, Vojtěch and Radová, Lenka and Filip, Daniel and Mráz, Marek and MontesandMojarro, I.A. and Prokoph, N. and Larose, H. and Liang, H.C. and Sharma, G.G. and Mologni, L. and Belada, D. and Kamaradova, K. and Fend, F. and GambacortiandPasserini, C. and Merkel, O. and Turner, Suzanne Dawn and Janíková, Andrea and Pospíšilová, Šárka},
article_location = {London},
article_number = {5},
doi = {http://dx.doi.org/10.1038/s41375-020-01093-1},
keywords = {ALCL},
language = {eng},
issn = {0887-6924},
journal = {Leukemia},
title = {STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma},
url = {https://www.nature.com/articles/s41375-020-01093-1},
volume = {35},
year = {2021}
}
TY - JOUR
ID - 1781892
AU - Lobello, Cosimo - Tichý, Boris - Bystrý, Vojtěch - Radová, Lenka - Filip, Daniel - Mráz, Marek - Montes-Mojarro, I.A. - Prokoph, N. - Larose, H. - Liang, H.C. - Sharma, G.G. - Mologni, L. - Belada, D. - Kamaradova, K. - Fend, F. - Gambacorti-Passerini, C. - Merkel, O. - Turner, Suzanne Dawn - Janíková, Andrea - Pospíšilová, Šárka
PY - 2021
TI - STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma
JF - Leukemia
VL - 35
IS - 5
SP - 1500-1505
EP - 1500-1505
PB - Nature Publishing Group
SN - 08876924
KW - ALCL
UR - https://www.nature.com/articles/s41375-020-01093-1
N2 - Systemic anaplastic large cell lymphoma (sALCL) encompasses two distinct clinical entities of T-cell non-Hodgkin lymphoma: anaplastic lymphoma kinase-positive (ALK+) ALCL and ALK-negative (ALK−) ALCL. These entities are characterized by either the presence or absence of an ALK translocation. It has been reported that ALK+ ALCL has a better prognosis compared to ALK−, with a 5-year overall survival (OS) of 70–80% versus 40–60%, respectively, [1,2,3]. Furthermore, more than 30% of ALK+ ALCL patients relapse [4, 5]. Despite the distinction between the two sALCL subtypes, frontline treatment for adults is similar and is based on CHOP or CHOEP, instead pediatric ALCL patients are mainly treated following the ALCL99 protocol [6,7,8]. Whilst high-throughput genomic studies in sALCL have shown recurrent genetic alterations, their association with outcome has not been fully investigated [9,10,11,12,13]. In this study, the mutational landscape of sALCL patient tumors was investigated to discover potential biomarkers that may improve risk stratification and patient management.
ER -
LOBELLO, Cosimo, Boris TICHÝ, Vojtěch BYSTRÝ, Lenka RADOVÁ, Daniel FILIP, Marek MRÁZ, I.A. MONTES-MOJARRO, N. PROKOPH, H. LAROSE, H.C. LIANG, G.G. SHARMA, L. MOLOGNI, D. BELADA, K. KAMARADOVA, F. FEND, C. GAMBACORTI-PASSERINI, O. MERKEL, Suzanne Dawn TURNER, Andrea JANÍKOVÁ and Šárka POSPÍŠILOVÁ. STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma. \textit{Leukemia}. London: Nature Publishing Group, 2021, vol.~35, No~5, p.~1500-1505. ISSN~0887-6924. Available from: https://dx.doi.org/10.1038/s41375-020-01093-1.
|
